Yuanyin Bio is emerging as a disruptive force in the Biopharma, Biotechnology, and Pharmaceutical sectors with its focus on circular RNA technology. Founded in 2021, the company aims to revolutionize the medical field through its commitment to creating innovative drugs and therapies.
The startup is building a robust pipeline of new drugs, targeting diseases that currently lack effective treatment options, thus addressing significant unmet clinical needs. Their vision aligns with their slogan: "Pioneering the future of medicine with groundbreaking RNA technology to tackle unmet clinical needs and develop novel preventive and therapeutic solutions."
In their recent round of funding, Yuanyin Bio secured a $42.00M Series A investment from a consortium of prominent investors including Cenova, MSA Capital, Quan Capital, 3H Health Investment, Sherpa Healthcare Partners, Tencent, and Sanzheng Health. This substantial financial backing underscores investor confidence in their potential to innovate within their industry.
